Education
About Us
Working with TipRanks
Follow Us
Rapt Therapeutics Inc (RAPT)
:RAPT
Total Valuation
RAPT Therapeutics has a market cap or net worth of $113.99M. The enterprise value is -$152.80M.
Market Cap$113.99M
Enterprise Value-$152.80M
Share Statistics
RAPT Therapeutics has 132.01M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding132.01M
Owned by Insiders6.10%
Owned by Instutions25.11%
Financial Efficiency
RAPT Therapeutics’s return on equity (ROE) is -0.68 and return on invested capital (ROIC) is -70.01%.
Return on Equity (ROE)-68.38%
Return on Assets (ROA)-54.04%
Return on Invested Capital (ROIC)-70.01%
Return on Capital Employed (ROCE)-70.90%
Revenue Per Employee$0
Profits Per Employee-$1,909,779.412
Employee Count68
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of RAPT Therapeutics is -0.50. RAPT Therapeutics’s PEG ratio is -0.11.
PE Ratio-0.50
PS Ratio0.00
PB Ratio0.34
Price to Fair Value0.34
Price to FCF-0.77
Price to Operating Cash Flow-0.77
PEG Ratio-0.11
Income Statement
In the last 12 months, RAPT Therapeutics had revenue of $0.00 and earned -$129.87M in profits. Earnings per share was -$3.11.
Revenue$0.00
Gross Profit-$619.00K
Operating Income-$136.10M
Pretax Income-$129.87M
Net Income-$129.87M
EBITDA-134.90M
Earnings Per Share (EPS)-3.11
Cash Flow
In the last 12 months, operating cash flow was -$83.30M and capital expenditures -$122.00K, giving a free cash flow of -$83.42M billion.
Operating Cash Flow-$83.30M
Free Cash Flow-$83.42M
Free Cash Flow per Share-$0.63
Dividends & Yields
RAPT Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-129.53%
Earnings Yield-201.65%
Stock Price Statistics
Beta1.68
52-Week Price Change-89.93%
50-Day Moving Average1.16
200-Day Moving Average1.78
Relative Strength Index (RSI)45.79
Average Volume (3m)854.50K
Important Dates
RAPT Therapeutics upcoming earnings date is May 8, 2025, Before Open.
Last Earnings DateMar 6, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
RAPT Therapeutics as a current ratio of 4.87, with Debt / Equity ratio of 0.02
Current Ratio4.87
Quick Ratio4.87
Debt to Market Cap0.07
Net Debt to EBITDA1.21
Interest Coverage Ratio0.00
Taxes
In the past 12 months, RAPT Therapeutics has paid $270.72K in taxes.
Income Tax$270.72K
Effective Tax Rate0.00%
Enterprise Valuation
RAPT Therapeutics EV to EBITDA ratio is 0.74, with an EV/FCF ratio of 1.21.
EV to Sales0.00
EV to EBITDA0.74
EV to Free Cash Flow1.21
EV to Operating Cash Flow1.21
Balance Sheet
RAPT Therapeutics has $231.06M in cash and marketable securities with $4.49M in debt, giving a net cash position of -$226.56M billion.
Cash & Marketable Securities$231.06M
Total Debt$4.49M
Net Cash-$226.56M
Net Cash Per Share-$1.72
Tangible Book Value Per Share$4.66
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for RAPT Therapeutics is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.00
Price Target Upside597.67%
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast
EPS Growth Forecast-2.29%